製品: NF kappaB p100/p52 Antibody
カタログ: AF6373
タンパク質の説明: Rabbit polyclonal antibody to NF kappaB p100/p52
アプリケーション: WB IHC IF/ICC IP
反応性: Human, Mouse, Rat
予測: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
分子量: 100kDa; 97kD(Calculated).
ユニプロット: Q00653
RRID: AB_2835217

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200, IP, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(100%), Bovine(100%), Horse(91%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%)
クローナリティ:
Polyclonal
特異性:
NF kappaB p100/p52 Antibody detects endogenous levels of total NF kappaB p100/p52.
RRID:
AB_2835217
引用形式: Affinity Biosciences Cat# AF6373, RRID:AB_2835217.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

CVID10; DNA binding factor KBF2; H2TF1; Lymphocyte translocation chromosome 10 protein; LYT 10; NF kB2; NFKB p52/p100 subunit; Nuclear factor Kappa B subunit 2; Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 (p49/p100); Nuclear factor of kappa light polypeptide gene enhancer in B cells 2; Oncogene Lyt 10; p100; Transcription factor NFKB2;

免疫原

免疫原:
Uniprot:
遺伝子(ID):
タンパク質の説明:
NFkB-p100 a transcription factor of the nuclear factor-kappaB ( NFkB) group. Precursor of the p52 subunit of the nuclear factor NF-kappa-B, which binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions.
タンパク質配列:
MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGPSHGGLPGASSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGICAVSVGPKDMTAQFNNLGVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKELKKVMDLSIVRLRFSAFLRASDGSFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENGWQAFGDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRKRRKALPTFSQPFGGGSHMGGGSGGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEAAEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGVTADARALLAGQRHLLTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVITGQTSVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEGLYPVHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRANVNARTFAGNTPLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGPEKDTRSSFRGHTPLDLTCSTKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQLLDGPEAQGSWAELAERLGLRSLVDTYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGLEEGVRLLRGPETRDKLPSTAEVKEDSAYGSQSVEQEAEKLGPPPEPPGGLCHGHPQPQVH

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Horse
91
Xenopus
70
Zebrafish
45
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q00653 基板として

Site PTM Type Enzyme
K19 Sumoylation
S22 Phosphorylation
S23 Phosphorylation
K28 Ubiquitination
K47 Ubiquitination
Y55 Phosphorylation
K72 Ubiquitination
K90 Sumoylation
T97 Phosphorylation
S99 Phosphorylation O15111 (CHUK)
S108 Phosphorylation O15111 (CHUK)
K112 Ubiquitination
S115 Phosphorylation O15111 (CHUK)
S123 Phosphorylation O15111 (CHUK)
K143 Ubiquitination
K144 Ubiquitination
K153 Ubiquitination
S161 Phosphorylation
T167 Phosphorylation
K179 Ubiquitination
S204 Phosphorylation
S222 Phosphorylation P49841 (GSK3B)
K229 Ubiquitination
K235 Ubiquitination
K252 Ubiquitination
S277 Phosphorylation
Y285 Phosphorylation
K298 Sumoylation
K321 Ubiquitination
Y325 Phosphorylation
Y326 Phosphorylation
K332 Ubiquitination
T429 Phosphorylation
T651 Phosphorylation
T655 Phosphorylation
T682 Phosphorylation
K689 Sumoylation
S707 Phosphorylation P49841 (GSK3B)
S711 Phosphorylation P49841 (GSK3B)
S713 Phosphorylation
S715 Phosphorylation
S717 Phosphorylation
S727 Phosphorylation
S739 Phosphorylation
K741 Ubiquitination
K743 Ubiquitination
S762 Phosphorylation
S802 Phosphorylation
S812 Phosphorylation
K855 Ubiquitination
S858 Phosphorylation
T859 Phosphorylation
K863 Sumoylation
S866 Phosphorylation Q99558 (MAP3K14)
Y868 Phosphorylation
S870 Phosphorylation Q99558 (MAP3K14)
S872 Phosphorylation O15111 (CHUK)

研究背景

機能:

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.

PTMs:

While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.

Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.

Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.

細胞の位置付け:

Nucleus. Cytoplasm.
Note: Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
サブユニット構造:

Component of the NF-kappa-B RelB-p52 complex. Homodimer; component of the NF-kappa-B p52-p52 complex. Component of the NF-kappa-B p65-p52 complex. Component of the NF-kappa-B p52-c-Rel complex. NFKB2/p52 interacts with NFKBIE. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Directly interacts with MEN1.

タンパク質ファミリー:

The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.

The glycine-rich region (GRR) appears to be a critical element in the generation of p52.

研究領域

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

参考文献

1). Astragaloside IV regulates NF‑κB‑mediated cellular senescence and apoptosis of hepatic stellate cells to suppress PDGF‑BB‑induced activation. Experimental and Therapeutic Medicine, 2019 (PubMed: 31641375) [IF=2.7]

Application: WB    Species: rat    Sample: HSC‑T6

Figure 6. |The expression of components in the NF‑κB pathway in platelet‑derived growth factor‑BB‑activated HSC‑T6 treated with ASIV. (A‑E) The relative mRNA expression levels of (A) p65, (B) p52, (C) p50, (D) IKKα and (E) IκBα. (F) Protein expression of p65, p52 and IκBα. *P<0.05 and **P<0.01. IKKα, inhibitor of nuclear factor‑κB kinase subunit‑α; IκBα, inhibitor of nuclear factor‑κB‑α; NF‑κB, nuclear factor‑κB; ASIV, astragaloside IV.

2). Fingolimod protects against cerebral ischemia reperfusion injury in rats by reducing inflammatory cytokines and inhibiting the activation of p38 MAPK and NF-κB signaling pathways. NEUROSCIENCE LETTERS, 2022 (PubMed: 34942319) [IF=2.5]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.